Samaritan Awarded NIH-STTR Grant to Develop Innovative Diagnostic Blood Test for Alzheimer's Disease.
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :SPHC):
-- Currently, Alzheimer's (AD) Is Truly Only Diagnosable After Death -- Our Collaborative Researchers Are First to Recognize the Relationship Between DHEA and Alzheimer's Disease -- Imagine A Simple, Minimally Invasive, Blood Test that Could: a. Allow a Doctor to Confidently Diagnosis Alzheimer's and Predict the Effectiveness of Current Medical Treatments b. Encourage and Reduce the Fear of Early Diagnosis c. Facilitate Earlier, Successful Treatments Which Could Delay the Progression of AD and Its Memory Loss
Samaritan Pharmaceuticals Inc. (OTCBB:SPHC) and Samaritan Research Labs, Georgetown University announced today that, Samaritan and Georgetown University, together, were awarded a National Institute of Health, Small Business Technology Transfer Program (NIH-STTR) grant, of $188,000, for its innovative idea to develop a simple blood test to predict Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . The National Institute of Neurological Disorders and Stroke The National Institute of Neurological Disorders and Stroke is a part of the U.S. National Institutes of Health.
The NINDS conducts and supports research on brain and nervous system disorders. Created by the U.S. will fund this research grant entitled "Plasma Diagnostic for Alzheimer's Disease Pathology."
Dr. Janet Greeson, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Samaritan commented, "We are extremely honored to have our science recognized and deemed worthy of receiving this grant. It is our first application and it adds immensely to the credibility of our scientific collaboration with Georgetown University. Secondly, according to the NIH "Not invented here." See digispeak.
NIH - The United States National Institutes of Health. website, we are the third company to be distinguished by receiving an STTR STTR Small Business Technology Transfer Program
STTR Small Technology Transfer Innovation Research award in Nevada's history."
This grant will support the research collaboration between Samaritan and Georgetown University, Washington, DC. Dr. Janet Greeson, Samaritan's Chief Executive Officer, will collaborate with Dr. Vasilli Papadopoulos, the grant's Principal Investigator. Dr. Papadopoulos is the Chair of the Department of Biochemistry, and Molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller , at Georgetown University Medical Center Georgetown University Medical Center (GUMC) is the medical campus at Georgetown University. It is co-located with Georgetown University Hospital on the University's main campus in Washington, DC. , and will be responsible for the development of this novel innovative diagnostic.
Dr. Papadopoulos stated, "Recently, Samaritan Research Laboratories, at Georgetown University, discovered a potential correlation between DHEA DHEA dehydroepiandrosterone.
n dehydroepiandrosterone, a hormone precursor, exists naturally in yams. precursor levels in blood plasma blood plasma
The yellow or gray-yellow, protein-containing fluid portion of blood in which the blood cells and platelets are normally suspended. , and Alzheimer's disease. It is this innovative correlation that could potentially be used to develop an inexpensive, minimally invasive, early detection biomarker for Alzheimer's disease. The overall objective of this grant is to differentiate between the levels of DHEA precursor in the plasma of patients with Alzheimer's, and normal individuals; and define the relationship between the levels of DHEA precursor, in plasma, and Alzheimer's."
Dr. Greeson added, "Unfortunately, by the time most Alzheimer's diagnoses are made, the family is the only one capable of understanding this horrendous diagnosis. Aside from early treatment, being able to make a major difference in a patient's involvement in their own care and possibly delaying Alzheimer's progression; perhaps, our biomarker development, will indicate a new way of treating this devastating dev·as·tate
tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates
1. To lay waste; destroy.
2. To overwhelm; confound; stun: was devastated by the rude remark. disease, until a cure for Alzheimer's can be found."
Small Business Technology Transfer Program (STTR)
STTR funds are dedicated to collaborations between universities and small businesses engaged in technology transfer, to promote the development of academic technologies into commercial applications. Success in Phase I will allow Samaritan to apply for additional funding via Phase II, which could support continual development of this Alzheimer's Diagnostic.
Alzheimer's is one of the most devastating and costly human conditions. It affects over 15 million people worldwide, causing memory loss and, ultimately, dementia. Alzheimer's disease usually begins gradually, causing a person to forget recent events or familiar tasks. How rapidly it advances varies from person to person, but the disease eventually leads to confusion, personality and behavior changes, and impaired judgment. Communication becomes more difficult as the disease progresses, leaving those affected struggling to find words, finish thoughts, or follow directions. Eventually, most people with Alzheimer's disease become unable to care for themselves.
Samaritan Pharmaceuticals: "A Cure Is Closer Than You Think."
Samaritan Pharmaceuticals is working to ensure a longer and better life, for patients suffering with AIDS, Alzheimer's, Cancer and Cardiovascular disease Cardiovascular disease
Disease that affects the heart and blood vessels.
Mentioned in: Lipoproteins Test
cardiovascular disease . Samaritan is an innovation-driven Biopharmaceutical, with a clear focus on clinical development. Its strategy is, to reduce the time, and expense, of commercializing drugs, by identifying, acquiring, and in-licensing novel compounds, from Universities.
Samaritan's marquee HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. drug, has demonstrated "proof of principle" by effectively reducing viral load viral load
The concentration of a virus, such as HIV, in the blood.
n a measure of the number of virus particles present in the bloodstream, expressed as copies per milliliter. . Upon the FDA's consent, Samaritan plans to commence Phase III human trials, to confirm the efficacy of its HIV drug, and monitor for adverse reactions adverse reactions,
n.pl unfavorable reactions resulting from administration of a local anesthetic; responsible factors include the drug used, concentration, and route of administration. with long term use.
Beyond its proprietary HIV drug, Samaritan has exclusively licensed twelve technologies from Georgetown University, building a robust, sustainable, pipeline of novel drugs to clinically develop, and commercialize for its future growth.
Visit our Web site at www.samaritanpharmaceuticals.com.
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 14, 2004. The company undertakes no duty to update forward-looking statements.